产品
编 号：F746916
分子式：C71H102N18O20
分子量：1527.68
分子式：C71H102N18O20
分子量：1527.68
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 176326-01-5
产品详情
生物活性：
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
体内研究：
Gliadin p31-43 (10 μg; intraluminally injection) shows a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro and induced activation of the apoptosis-associated speck-like (ASC) complex.The increment of IL-1β indicates the activation of the inflammasome caspase-1 pathway in the small intestine mucosa by oral administration of Gliadin p31-43 (20 μg) in wild type C57Bl/6 mice. Gliadin p31-43 has an intrinsic propensity to form oligomers which trigger the NLRP3 inflammasome.
体外研究：
Gliadin p31-43 (100?μg/mL; 30 minutes-6 hours) treatment induces the MyD88/TLR7 complexes, and activates downstream signalling by activating MAPKs, ERK, JNK and p38). Gliadin p31-43 increases the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38).Gliadin p31-43 treatment increases NF-κB phosphorylation in CaCo-2 cells from 0.45?in control cells to 0.86. Gliadin p31-43 treatment induces a significant increase in levels of the MxA protein. The levels of the IFN-α 7 and 17 mRNAs are also analysed after Gliadin p31-43 treatment.In CaCo-2 cells, Gliadin p31-43 localizes to the early endosomes and delays vesicular trafficking. Gliadin p31-43 interferes with the correct localization of the growth factor regulated tyrosine kinase substrate (HRS) to early endosomes, delaying the maturation of the endocytic vesicles.
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
体内研究：
Gliadin p31-43 (10 μg; intraluminally injection) shows a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro and induced activation of the apoptosis-associated speck-like (ASC) complex.The increment of IL-1β indicates the activation of the inflammasome caspase-1 pathway in the small intestine mucosa by oral administration of Gliadin p31-43 (20 μg) in wild type C57Bl/6 mice. Gliadin p31-43 has an intrinsic propensity to form oligomers which trigger the NLRP3 inflammasome.
体外研究：
Gliadin p31-43 (100?μg/mL; 30 minutes-6 hours) treatment induces the MyD88/TLR7 complexes, and activates downstream signalling by activating MAPKs, ERK, JNK and p38). Gliadin p31-43 increases the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38).Gliadin p31-43 treatment increases NF-κB phosphorylation in CaCo-2 cells from 0.45?in control cells to 0.86. Gliadin p31-43 treatment induces a significant increase in levels of the MxA protein. The levels of the IFN-α 7 and 17 mRNAs are also analysed after Gliadin p31-43 treatment.In CaCo-2 cells, Gliadin p31-43 localizes to the early endosomes and delays vesicular trafficking. Gliadin p31-43 interferes with the correct localization of the growth factor regulated tyrosine kinase substrate (HRS) to early endosomes, delaying the maturation of the endocytic vesicles.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备